Eric Lefkofsky is one of the most successful entrepreneurs that the country has ever seen. He already has three companies that have gone public, namely Echo Global Logistics, Groupon and InnerWorkings. After the success of his e-commerce company, he is interested in doing something in the health industry. He understood that there was a big gap between technology advancement and the health industry and wants to bring them both together to strengthen the industry. Even though big data has already been used in many different industries, its usage in the health industry is quite small. He wants to change this by developing Tempus. Tempus is a company that will compile genomic data to allow doctors to provide personalised treatment therapy depending on the condition of the patient.
Eric Lefkofsky was one of the founding members of the company and has been with the company since 2015. It was him who had the idea about the company and him along with other members brought it to life through Tempus. In a small amount of time the company has managed to draw the attention of the top most doctors and physicians as they feel it this big data company will allow them to find information quickly which is often important for them in treating their patients. They not only collect the data but have computer engineers who write algorithms to be able to analyze this data in an in-depth manner. Many health departments of institutions and hospitals have already formed a partnership with them, and they share their data with the company that can be used by them later on. Click here to know more.
Even though Mr. Eric is busy with his work commitment, he takes out time to indulge in charity events across the country. He and his wife started a family foundation in 2006 and had also signed the Giving Pledge. Over the years, their foundation has helped many different public and private organizations that are working towards the benefit of the community as a whole. Apart from that, he is also on the board of many different organizations like the Children’s Memorial in Chicago and the Art Institute of Chicago.
The current president and CEO of Seattle Genetics is Clay B. Siegall, Ph.D. He cofounded Seattle Genetics in 1998. He is an expert in science and biotechnology. He is talented and highly trained in the field of science and innovations. He is also a great entrepreneur. Dr. Siegall was named as the entrepreneur of the year in the region of Pacific Northwest back in 2012. He has been in leadership for many years and hence, he has great and admirable experience. His leadership techniques are spectacular because of his excellent knowledge and ability to work with a team of experts.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Education background and experience of Dr. Siegall
Dr. Clay Siegall is a Doctor of Philosophy which was a great achievement at George Washington University in the USA. Siegall holds a bachelor’s degree in Science (Zoology) from the University of Maryland. He is a great leader and an individual with a great passion for science and innovation. His skills have enabled him to achieve more his roles of leadership. It is proved by the many organizations that he leads. He is also a director in many companies which include Ultragenix Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals.
The foundation of Seattle Genetics
It was established back in 1998 under the leadership of Dr. Clay Siegall. He was driven by the passion for helping the patients who are needy in the opening of the company. The company was built on great scientific innovations and thorough research. The company has achieved more under the supervision of Dr. Clay Siegall. One of the biggest achievements of the company is the invention of the (ADCs) antibody drugs conjugates. The drugs were approved in a ceremonial event by the US government in the administration of medications and food back in 2011. The drugs gained popular recognition countrywide.
Dr. Siegall has led the company to the achievement of many other things. It is now a stable company in the field of biotechnology. The company serves a large number of patients from the US and other foreigners. It has won several honorary awards has invested in many areas. The company has an excellent vision and objectives of becoming a global leader in cancer treatment and biotechnology.